6th Annual Pathways to Access & Reimbursement

EXCLUSIVE UPDATES FROM pCPA, CADTH and Health Canada

January 21, 2021 Eastern Standard Time

Virtual Conference

6th Annual

PATHWAYS TO ACCESS & REIMBURSEMENT Canada’s premier forum on navigating market entry and developing effective pricing strategies

FORMERLY KNOWN AS

PHARMA SYMPOSIUM

CO-CHAIRS:

Alexis Sciuk Director of Access & Government Relations Pfizer

Rosemarie Childerhose Director, Market Access & Government Affairs Bausch Health

TIMELY INSIGHTS FROM: • Pfizer • Canada Life • CADTH

Attend this forward-looking forum, designed to bring clarity to some of the greatest challenges facing manufacturers, patients, and payers alike in this radically altered healthcare climate.

CHEVRON-RIGHT ASSESS the impact of new PMPRB guidelines on drug pricing in Canada and implications for different stakeholders CHEVRON-RIGHT PREPARE for a new drug procurement model under Canada’s National Pharmacare strategy CHEVRON-RIGHT ACCELERATE access with advice on HTA submissions and public and private payer negotiations CHEVRON-RIGHT OBTAIN insights on new emergency regulatory tools for COVID-19 vaccine development, testing, and patient access

• Health Canada • Sun Life

Associate Sponsor:

CanadianInstitute.com/PathwaystoAccess • 877 927 7936

Media Partners:

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

Distinguished Faculty

Sweeping changes are coming to how drugs are priced, procured and reimbursed in Canada but many of the details have yet to be solidified. While the industry grapples with these ongoing changes, a global pandemic has created a new focal point: identifying viable COVID-19 treatments and supporting scientific advancements towards vaccine.

It’s a critical time for stakeholders to come together and learn about how regulatory bodies could potentially work together under a National Drug Agency and the implications of new pricing ceilings.

CONFERENCE CO-CHAIRS:

Alexis Sciuk Director of Access & Government Relations Pfizer Rosemarie Childerhose Director, Market Access & Government Affairs Bausch Health DISTINGUISHED SPEAKERS:

Gail Attara President & Chief Executive Officer Gastrointestinal Society Megan Bettle Director, General, COVID-19 Regulatory Response Team Health Canada Tijana Fazlagic Executive Director, PharmaCare Benefits Branch BC Ministry of Health

At this juncture, collaboration and transparency are paramount to patient access and improved health outcomes.

Brent Fraser Vice-President Pharmaceutical Reviews CADTH

Prepare to build your pricing and access strategy for 2021 and beyond through conversations and in-depth analysis about:

John Helou Former President & CEO Pfizer

CHEVRON-RIGHT OPTIMIZING pCPA negotiations with advice on current and impending policy positions CHEVRON-RIGHT UNDERSTANDING how PMPRB reform and National Pharmacare models could impact the Canadian market

Daphne Lainson Partner Smart & Biggar LLP Barbara Martinez Practice Leader, Drug Solutions Canada Life

CHEVRON-RIGHT ASSESSING the emergence of new HTA frameworks

Daniel McLean Senior Manager pCPA

CHEVRON-RIGHT IDENTIFY OPPORTUNITIES to create partnerships and advance your market access strategy

Dr. Nicole Mittmann Chief Scientist and Vice-President Evidence Standards CADTH

Handshake-alt Global Sponsorship Opportunities With conferences in the United States, Europe, Asia Pacific, and Latin America, the C5 Group of Companies: American Conference Institute, The Canadian Institute, and C5 Group, provides a diverse portfolio of conferences, events and roundtables devoted to providing business intelligence to senior decision makers responding to challenges around the world.

Don’t miss the opportunity to maximize participation or showcase your organization’s services and talent. For more information please contact us at: SponsorInfo@CanadianInstitute.com

2 | #CIPathways

Ned Pojskic Vice President, Pharmacy Benefits Management Green Shield Canada Zal Press Vice Chair, Patient and Community Advisory Committee CADTH Durhane Wong Rieger President CORD George Wyatt Executive Senior Consultant Innomar Strategies

twitter: @CI_Healthcare linkedin: Healthcare, Pharmaceutical and Medical Device Network

Thursday, January 21, 2021 EST 8:15

Opening Remarks from the Co-Chairs

MICROPHONE Alexis Sciuk,Director of Access & Government Relations, Pfizer

Rosemarie Childerhose, Director, Market Access & Government Affairs, Bausch Health

8:30

KEYNOTE

CADTH: What Industry Can Expect from an HTA Perspective amid the Pandemic

MICROPHONE Dr. Nicole Mittmann, Chief Scientist and Vice-President Evidence Standards, CADTH

9:00

Preparing for PMPRB Final Guidelines: A Examination of the Practical Impact on Drug Pricing in Canada

MICROPHONE Daphne Lainson, Partner, Smart & Biggar LLP • Analyzing the final PMPRB guidelines: From revised reference countries to the use of pharmacoeconomics • Conducting an impact analysis on grandfathered products, line extensions, gap medicines and new medicines • Understanding patent and other exclusivities on the market • Assessing and managing cross-border market access issues 9:45

Morning Break

This candid conversation with John Helou will provide a glimpse into an illustrious career in the pharmaceutical industry at one of Canada’s leading brand manufacturers. He will offer critical perspectives on how to create a path forward within the pharmaceutical sector that best serves the needs of Canadians.

1:45

Breaking Down the Decision to Switch: Lessons from the B.C. Biosimilars Initiative

MICROPHONE Tijana Fazlagic, Executive Director, PharmaCare Benefits Branch, BC Ministry of Health

On May 27, 2019, British Columbia embarked on a multi-stage strategy to switch patients on certain biologics to biosimilars to curtail drug expenditures under its PhamaCare program. The decision to discontinue coverage for three of the costliest biologics in favour of biosimilars is expected to save $100-million over the next three years. Other provincial payers are now contemplating a similar policy.

In this session: • Learn about the analysis for province’s biosimilars policy decision and subsequent implementation • How to keep the patient at the center of the decision-making process • Examine early results: how has the decision impacted health outcomes?

2:45

Afternoon Break

3:15

Approaches to Reimbursement for Advanced Therapeutics

MICROPHONE Barbara Martinez, Practice Leader, Drug Solutions, Canada Life

10:15

Forecasting Future Pathways for Access and Reimbursement in the Canadian Market

MICROPHONE Brent Fraser, Vice-President Pharmaceutical Reviews, CADTH

• Gain insights on how different private payer are developing policies for biosimilars

Daniel McLean, Senior Manager, pCPA Change is on the horizon, from steps towards a National Drug Agency to pricing reforms for patented medicines, as such, the pharmaceutical industry in Canada could look very different in the coming years.

In this session, engage in constructive, forward-looking dialogue about where opportunities for collaboration exist and the implications for manufacturers as they try to map out their market access strategy.

• Understanding how regulatory bodies envision working together to procure drugs under a National Drug Agency • Comparing single payer systems with multi-payer • Assessing how the proposed reforms will impact current formularies • Developing plans for how manufacturers can prepare for new pathways to access and reimbursement 11:15

Supporting Access to COVID-19 Products – Health Canada’s Regulatory Response

MICROPHONE Megan Bettle, Director, General, COVID-19 Regulatory Response Team, Health Canada

• Responding to COVID-19: Health Canada operational flexibilities and engaging with manufacturers • Developing agile regulatory tools – interim orders • Devising approaches to the review of COVID-vaccines

Ned Pojskic, Vice President, Pharmacy Benefits Management, Green Shield Canada

• Understand how provincial trends are impacting private payer decisions • Examine payment models being considered for gene therapies • High cost drugs: What happens when patient switches payers • Explore the implications of managed formularies 4:15

Creating Partners in Access & Reimbursement: Building Better Relationships with Advocates and Infrastructure for Patients

MICROPHONE Zal Press, Vice Chair, Patient and Community Advisory Committee, CADTH

Durhane Wong Rieger, President, CORD George Wyatt, Executive Senior Consultant, Innomar Strategies MODERATOR:

Gail Attara, President & Chief Executive Officer, Gastrointestinal Society

Access and Reimbursement policy decisions can be life altering for those in need of innovative therapies. In this session: • Hear from patient advocates within the Canadian healthcare system about their perspectives on recent changes within the current pharmaceutical landscape

12:15

1:1 Networking and Lunch

• Learn about how they envision working with industry to improve patient access

1:15

FIRESIDE CHAT

• Identify opportunities to create partnerships and advance your market access strategy

Top 5 Takeaways from a Career in the Pharmaceutical Industry and Insights on How to Support Pathways to Access 2021 and Beyond

MICROPHONE John Helou, Former President & CEO, Pfizer CanadianInstitute.com/PathwaystoAccess • 877 927 7936

• Gain insights on patient perspectives on current pathways to access & reimbursement and where they would like to see change 5:00

Conference Concludes

Part of C5 Group’s LIFE SCIENCES GLOBAL SERIES

“

TEAM LEAD, PRICING AND CONTRACTS, GSK:

Great overview, gave me a different perspective.

Got me thinking differently.

MANAGER, MARKET ACCESS AND HTA, BMS:

I liked the quality of the speakers.

LEAD PAYER STRATEGY, HEALTH ECONOMICS AND OUTCOMES, SANOFI:

Networking sessions were valuable.

MANAGER, PRICING AND CONTRACTS, ASTELLAS:

Overall excellent topics and speakers.

Truly enjoyed the selection of speakers and the panels.



WHO SHOULD ATTEND



\ Practitioners at every level with experience in: -

Pricing Reimbursement Market access Patient access Government and regulatory affairs Health economics Research and development

-

Policy and compliance Pharmacy services Marketing National trade Formularies Business development Sales

”

Join Our Email List to Stay Connected

SIGN UP TO RECEIVE EXCLUSIVE DISCOUNTS, OFFERS AND PROGRAM UPDATES CanadianInstitute.com/elist/

About us:

\ From brand generic and manufacturing companies involved in: -

Product development Public drug programs Pharmaceutical benefits Pharmaceutical strategy Drug submissions

- Formulary management - Policy and economic analysis - Provider services and relations - Pharmacy

The C5 Group, comprising American Conference Institute, The Canadian Institute and C5 in Europe, is a leading global events and business intelligence company.

For over 35 years, C5 Group has provided the opportunities that bring together business leaders, professionals and international experts from around the world to learn, meet, network and make the contacts that create the opportunities.

\ And representatives from: - Associations

Our conferences and related products connect the power of people with the power of information, a powerful combination for business growth and success.

- Patient Advocacy Groups

3 Ways to Register 

ONLINE:



CanadianInstitute.com/PathwaystoAccess

SAVE $200

Register & Pay by December 11, 2020

EMAIL:



CustomerService@CanadianInstitute.com

SAVE $100

Register & Pay by December 31, 2020

$895

1-877-927-7936

REGISTRATION CODE:

Register & Pay after December 31, 2020

B00-350-350X21.WEB CONFERENCE CODE:

*APPLICABLE TAXES WILL BE ADDED TO ALL REGISTRATIONS Virtual Conference

PHONE:

$995

350X21-VRT

$1095

Bringing a Team?

*The amount of tax charged on your order will be determined based on the product type purchased and tax regulations.

To update your contact information and preferences, please visit https://www.canadianinstitute.com/preference-centre/.

Refund and cancellation policies can be found at https://www.canadianinstitute.com/company/faq/.

To learn more or read our terms of services, visit: https://www.canadianinstitute.com/terms-services/.

3-4

10% Conference Discount

5+

Call 416-927-7936

Special Discount Call 1-877-927-7936 for Group or Special Industry Pricing Options

© The Canadian Institute, 2020

C5 GROUP’S VIRTUAL EVENTS

Re-imagining the way we deliver professional development Collaboration is more vital than ever and for that, you can still rely on CI to bring the industry together but in a different way. We are transforming quickly to ensure you can now connect virtually and continue to gain unparalleled access to market leading intelligence and to the facilitation of a global exchange of expertise.

Our new virtual events continue to be guided by our unifying philosophy: we believe that growth and success occurs when the power of people and the power of information come together. We may not be able to gather in person, but nothing stops connection and innovation.

What you can expect at this virtual series This new virtual series delivers the same access to a community of industry leaders we have spent decades building and nurturing. We invite you to be part of this community.

PLAY VIEW DEMO

Expand your network to a global audience.

Immerse yourself in live presentations, panel discussions, specialized breakout sessions and networking opportunities.

Engage in meaningful dialogue with attendees and speakers in an interactive format.

Meet 1-on-1 with attendees you select and exchange contact information for lasting connections and true engagement.

To view the complete list of our events, please visit:

CanadianInstitute.com/Conferences/Virtual

Visit solution providers and learn about the latest technologies, services and products.

PIGGY-BANK

Eliminate the costs and stress of travel.

Hand-holding-seedling

Reduce waste and carbon footprint through this environmentally friendly platform.